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Hepatocellular Carcinoma Treated with Microwave Ablation Prior to Liver 
Transplantation 
Nicole Wagner, Amanda Smolock*, Michael Markovitz, Varun Danda, Christopher 
Neely, Warren Maley, Jesse Civan, Colette Shaw 
 
Introduction: Ablation is a minimally invasive procedure that limits local liver tumor 
progression and prolongs patients’ transplantation eligibility. Microwave ablation (MWA) 
utilizes higher temperatures than the standard of care, radiofrequency ablation (RFA), 
which increases efficiency. Meta-analyses compared MWA with RFA for the treatment 
of HCC and showed similar efficacy and safety between these modalities. However, 
limited pathologic data exists determining whether explanted tumors remained viable 
after MWA.  
Methods: Our database was reviewed retrospectively for patients with HCC who 
underwent MWA prior to liver transplantation between 2013 and 2019. Patient 
demographics, etiology of disease, tumor size, procedure details, bilirubin, MELD, and 
Child-Pugh score were reviewed. Tumors were classified as viable or nonviable based 
on pathology. Imaging and clinical follow-up were available for surveillance and post-
transplant. 
Results: 29 patients (23 males, 6 females) with 40 tumors underwent MWA. The 
average patient age was 60 years. The mean tumor size was 2.2 cm (range 1-3.7). 
Twenty-six patients were alive at follow-up. Pathological analysis showed 38 of the 40 
tumors ablated to be non-viable at explant. Imaging prior to transplant reported one 
case with recurrent tumor at the ablation site and another case as equivocal. No cases 
of metastatic HCC were identified by imaging post-transplant.     
Discussion: Previous studies have not included this pathologic data. Determining 
tumor viability provides valuable information regarding whether tumors are likely to recur 
locally, even after transplantation. These results suggest that MWA is an effective 
treatment of small HCC prior to transplant with a low incidence of local tumor 
recurrence. 
